Австралия - английский - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: water for injections; mannitol; sodium hydroxide; sulfuric acid - vincristine sulfate injection is indicated in acute leukemia. vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, and wilm's tumor.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cytarabine,sodium chloride -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - carboplatin is indicated in the treatment of ovarian cancer of epithelial origin and in second line therapy after other treatments have failed.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - hyoscine hydrobromide -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sulfuric acid; sodium hydroxide - not applicable - to be used as part of the liposome injection kit. details are owned by the licence holder, not hospira.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - sodium thiosulfate -

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

hospira nz ltd - erythromycin lactobionate 1000mg;   - powder for injection - 1000 mg - active: erythromycin lactobionate 1000mg  

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

hospira nz ltd - erythromycin lactobionate 300mg;   - powder for injection - 300 mg - active: erythromycin lactobionate 300mg  

Ирландия - английский - HPRA (Health Products Regulatory Authority)

hospira uk limited - docetaxel - concentrate for soln for inf - 10 micromol - docetaxel

Европейский союз - английский - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.